European Innovation Council

Established in 2020, the European Innovation Council supports innovative startups and researchers with promising ideas, focusing on early-stage companies with positive environmental, social, or governance impacts. It co-invests alongside private investors.

Nicklas Bergman

Strategic Advisor and IC member

Francoise Birnholz

Affiliate Member

David Malo Jean

Director

Past deals in Southwestern Europe

VSORA

Venture Round in 2025
VSORA develops digital signal processing IP and chips for 5G networks, featuring a multicore DSP architecture that removes the need for DSP coprocessors and a shared DSP development flow that unites signal processing and software engineers in one environment to speed time-to-market. The company aims to boost DSP computing power while reducing power consumption, improving system performance, and shrinking silicon footprint. Based in France, founded in 2015 by veteran DSP engineers, VSORA serves chipmakers designing next-generation digital communications systems.

Wooptix

Series C in 2025
Wooptix S.L., founded in 2014 and headquartered in Madrid, Spain, specializes in developing advanced imaging technologies. The company focuses on light field and wavefront phase imaging software that captures comprehensive information about light, utilizing the full resolution of sensors. Wooptix's platform enables the three-dimensional modulation of images, allowing for higher data points at elevated frame rates in volumetric images and videos. This technology facilitates enhanced image quality and advanced post-processing capabilities, providing users with innovative ways to interact with and visualize their environments. Wooptix aims to improve human experiences through its cutting-edge imaging solutions.

TENSIVE

Series A in 2025
TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

Onward

Grant in 2024
Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

INBRAIN Neuroelectronics

Series B in 2024
INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

Axelera AI

Series B in 2024
Axelera AI specializes in developing hardware and software platforms designed to accelerate artificial intelligence tasks, particularly for edge computing. Its flagship product, the Metis™ AI Platform, integrates both hardware and software components to deliver high-performance, energy-efficient AI inference solutions. The company is headquartered in Eindhoven with R&D offices in Belgium, Switzerland, and Italy.

Tilkal

Venture Round in 2024
Tilkal develops a software infrastructure that organizes traceability across various supply chain stakeholders. Founded in 2017, the company is headquartered in Paris, France.

Ability Pharmaceuticals

Venture Round in 2024
Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Multiverse Computing

Series A in 2024
Multiverse Computing SL is a software development company based in San Sebastian, Spain, with an additional office in Toronto, Canada. Established in 2019, the company specializes in creating quantum computing software that leverages probabilistic and nondeterministic technologies to address complex challenges in various sectors, particularly finance. Multiverse Computing's software solutions are designed for portfolio optimization, risk analysis, and market simulation, enabling clients in industries such as banking, energy, manufacturing, and logistics to harness the power of quantum computing. By focusing on these tailored applications, the company aims to facilitate advancements in solving financial and macro-economic problems, positioning itself as a key player in the emerging quantum technology landscape.

Daze

Series A in 2024
Daze is an engineering startup focused on creating innovative solutions for electric vehicle charging. Its flagship product, DazePlug, is an automatic charging device that utilizes smart charging ecosystems and energy management systems. This technology enables automatic inductive charging, significantly reducing the time required to charge electric vehicles while eliminating the need for manual handling of cables. DazePlug features a retrofit design that is both waterproof and dustproof, ensuring durability and ease of use. By simplifying the charging process, Daze aims to enhance user experience and convenience for electric vehicle owners.

Palobiofarma

Venture Round in 2024
Palobiofarma is a Spanish biotechnology company based in Barcelona’s Science Park, dedicated to discovering and developing innovative drugs that target adenosine receptors. The company aims to be the first European entity to bring an adenosine modulator to market, focusing on the treatment of diseases such as advanced prostate cancer. Through its expertise in medicinal chemistry and in vitro pharmacology, Palobiofarma is committed to advancing the understanding of adenosine's role in disease and enabling healthcare professionals to improve patient outcomes through novel therapeutic options.

NETRIS Pharma

Series A in 2023
NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.

Antabio

Series B in 2023
Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

Ignion

Venture Round in 2023
Founded in 2015, Ignion specializes in designing and manufacturing antennas tailored for mobile and wireless connectivity. Their off-the-shelf antennas cater to Internet of Things devices, mobile connectivity, and short-range wireless systems, facilitating seamless integration within industrial designs.

VSORA

Grant in 2023
VSORA develops digital signal processing IP and chips for 5G networks, featuring a multicore DSP architecture that removes the need for DSP coprocessors and a shared DSP development flow that unites signal processing and software engineers in one environment to speed time-to-market. The company aims to boost DSP computing power while reducing power consumption, improving system performance, and shrinking silicon footprint. Based in France, founded in 2015 by veteran DSP engineers, VSORA serves chipmakers designing next-generation digital communications systems.

Epigene Labs

Convertible Note in 2023
Epigene Labs SAS is a biotechnology firm focused on enhancing precision oncology through its advanced technology platform that utilizes artificial intelligence. Founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, the company addresses the significant challenges of aggregating, analyzing, and visualizing extensive genomic data in cancer research. By integrating proprietary data from partners with publicly available datasets, Epigene Labs provides medical researchers with actionable insights and user-friendly analytics. The company collaborates with leading cancer centers and prominent biotech firms to develop intelligence-augmenting services that support drug discovery and research in precision oncology. Its innovative approach aims to transform genomic data into effective strategies for targeted cancer therapies.

INBRAIN Neuroelectronics

Grant in 2023
INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

Scipio Bioscience

Convertible Note in 2023
Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

Wooptix

Grant in 2023
Wooptix S.L., founded in 2014 and headquartered in Madrid, Spain, specializes in developing advanced imaging technologies. The company focuses on light field and wavefront phase imaging software that captures comprehensive information about light, utilizing the full resolution of sensors. Wooptix's platform enables the three-dimensional modulation of images, allowing for higher data points at elevated frame rates in volumetric images and videos. This technology facilitates enhanced image quality and advanced post-processing capabilities, providing users with innovative ways to interact with and visualize their environments. Wooptix aims to improve human experiences through its cutting-edge imaging solutions.

Wooptix

Series B in 2023
Wooptix S.L., founded in 2014 and headquartered in Madrid, Spain, specializes in developing advanced imaging technologies. The company focuses on light field and wavefront phase imaging software that captures comprehensive information about light, utilizing the full resolution of sensors. Wooptix's platform enables the three-dimensional modulation of images, allowing for higher data points at elevated frame rates in volumetric images and videos. This technology facilitates enhanced image quality and advanced post-processing capabilities, providing users with innovative ways to interact with and visualize their environments. Wooptix aims to improve human experiences through its cutting-edge imaging solutions.

Energy Dome

Series B in 2023
Energy Dome develops a low-cost, efficient system for long-duration electricity storage using liquid CO2. Its focus is on enabling dispatchable renewable energy production to facilitate the decarbonization of the energy industry and promote sustainability.

ADmit Therapeutics

Venture Round in 2023
ADmit Therapeutics is a biotechnology company that develops diagnostic tests for early detection of Alzheimer’s disease. Its blood-based assay uses epigenetic analysis to assess mitochondrial DNA methylation, including methylcytosines, through next-generation sequencing, and does not rely on beta-amyloid or tau markers. The test is intended to aid pharmaceutical research by enabling early diagnosis and streamlined drug development. The company was founded in 2017 and is based in Begues, Spain.

Voiseed

Venture Round in 2023
Voiseed is an Italian startup focused on artificial intelligence in synthetic speech technology. The company has developed a fast and scalable AI Dubbing Platform specifically for the video game industry, enabling the creation of virtual human voices that mimic human emotions and prosody. This cloud-based software leverages advanced generative AI technologies to produce highly expressive virtual voices, allowing creators to customize vocal expressions and achieve multilingual voice conversion for various projects. By streamlining the dubbing process, Voiseed aims to reduce costs, time, and complexity, while continuously expanding its features to cater to additional sectors beyond gaming.

Ganymed Robotics

Series B in 2023
Ganymed Robotics is a medical device company that develops robotics technologies for orthopedic surgeons, including a therapeutic device designed to improve precision in knee replacement procedures. Founded in 2018 and based in Paris, the company aims to enhance surgical accuracy, reduce operating times, and improve patient outcomes by integrating robotics into the orthopedic workflow.

Daze

Convertible Note in 2022
Daze is an engineering startup focused on creating innovative solutions for electric vehicle charging. Its flagship product, DazePlug, is an automatic charging device that utilizes smart charging ecosystems and energy management systems. This technology enables automatic inductive charging, significantly reducing the time required to charge electric vehicles while eliminating the need for manual handling of cables. DazePlug features a retrofit design that is both waterproof and dustproof, ensuring durability and ease of use. By simplifying the charging process, Daze aims to enhance user experience and convenience for electric vehicle owners.

Energy Dome

Grant in 2022
Energy Dome develops a low-cost, efficient system for long-duration electricity storage using liquid CO2. Its focus is on enabling dispatchable renewable energy production to facilitate the decarbonization of the energy industry and promote sustainability.

Nexdot

Pre Seed Round in 2022
Nexdot is a company specializing in the development and production of semiconductor nanocrystals known as Quantum Dots, with a particular focus on nanoplatelets—two-dimensional nanosheet Quantum Dots that exhibit enhanced properties. Originating as a spin-off from a renowned academic laboratory in Paris, Nexdot leverages over a decade of expertise in nanomaterial research. The company has invested four years in intensive research and development to establish unique capabilities in the synthesis of colloidal Quantum Dots and Nanoplatelets. Their proprietary materials, characterized by controlled shape and composition, are designed for a variety of applications, including displays, lighting, energy storage, detectors, and bio-imaging. Nexdot combines a team of highly skilled, passionate scientists with seasoned executives who possess a strong background in management and innovation leadership, positioning the company as a leader in the field.

Carmat

Post in 2022
Carmat is a French medtech company that specializes in the development and manufacturing of bioprosthetic artificial hearts. Founded in 2008 and headquartered in Vélizy-Villacoublay, the company creates biocompatible, auto-regulated total artificial hearts designed to closely mimic the human heart's structure, including both right and left ventricles. These devices are intended for patients suffering from chronic terminal heart failure classified as class IV by the New York Heart Association, as well as those experiencing acute terminal heart failure due to massive myocardial infarction. Carmat aims to provide a reliable and innovative therapeutic solution for heart failure patients who are ineligible for transplants and have exhausted other treatment options. In addition to the artificial hearts, the company develops the necessary power supply systems and remote diagnostic systems for these devices.

TENSIVE

Venture Round in 2022
TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

Newronika

Grant in 2022
Newronika is a company dedicated to restoring brain and body functions through innovative neuro-modulation technologies. It translates extensive expertise in biosignal decoding into clinical applications aimed at enhancing treatments, health, and overall wellness. By utilizing a therapeutic device that employs a retro-activity system, Newronika records brain activity and modulates neuro-stimulation to analyze and interpret bio-signals. This technology ensures that patients receive the appropriate stimulation at critical moments, enabling them to engage in normal daily activities and improve their quality of life. Founded as a spin-off from two prominent Italian research institutions, the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan, Newronika prides itself on a multidisciplinary team of scientists specializing in various fields, including neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnologies.

Carmat

Grant in 2022
Carmat is a French medtech company that specializes in the development and manufacturing of bioprosthetic artificial hearts. Founded in 2008 and headquartered in Vélizy-Villacoublay, the company creates biocompatible, auto-regulated total artificial hearts designed to closely mimic the human heart's structure, including both right and left ventricles. These devices are intended for patients suffering from chronic terminal heart failure classified as class IV by the New York Heart Association, as well as those experiencing acute terminal heart failure due to massive myocardial infarction. Carmat aims to provide a reliable and innovative therapeutic solution for heart failure patients who are ineligible for transplants and have exhausted other treatment options. In addition to the artificial hearts, the company develops the necessary power supply systems and remote diagnostic systems for these devices.

INBRAIN Neuroelectronics

Grant in 2022
INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

INBRAIN Neuroelectronics

Venture Round in 2022
INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

ELEM Biotech

Pre Seed Round in 2022
ELEM Biotech SL is a biomedical software company based in Barcelona, Spain, that specializes in creating virtual human models through advanced mathematical modeling and cloud computing. Founded in 2018 by researchers from the Barcelona Supercomputing Center, ELEM has developed a suite of simulation tools known as Alya Red. This platform operates on a Software-as-a-Service model and is designed for the medical device and pharmaceutical industries. Alya Red allows for the simulation of cardiovascular and respiratory systems on virtual patients, utilizing high-performance computing, computational biomechanics, and data analysis. These virtual avatars enable biomedical companies and healthcare professionals to enhance diagnostics, plan treatments, optimize drug delivery, and improve medical devices.

Cailabs

Series C in 2022
CAILabs SAS is a French deep tech company headquartered in Rennes, specializing in the design, development, and production of photonic solutions aimed at optimizing light utilization in various applications. Established in 2013, CAILabs focuses on innovative optical components, particularly through its patented Multi-Plane Light Conversion (MPLC) technology. The company provides a range of products, including mode multiplexers, light converters, and laser beam shaping solutions tailored for the telecommunications and industrial laser sectors. Its offerings are designed to enhance the performance of fiber optic networks and laser material processing, addressing critical challenges such as atmospheric turbulence and the need for efficient signal multiplexing. CAILabs aims to leverage its expertise and technological innovations to create reliable and cost-effective solutions for clients in the photonics industry.

ROSI

Series A in 2022
ROSI is a company based in Grenoble, France, focused on developing innovative technologies for the recycling and revalorization of raw materials within the photovoltaic industry. The company specializes in recovering ultra-pure silicon and other metals that are typically lost during the manufacturing of photovoltaic cells and at the end of a solar panel's life cycle. By addressing industrial waste generated during the solar wafer slicing process and capturing silicon fine particles lost during PV-silicon production, ROSI enables its clients to produce photovoltaic modules in a more sustainable and cost-effective manner.

APIX Analytics

Venture Round in 2022
Founded in 2014, APIX Analytics specializes in developing miniaturized multigas analyzers systems. These systems integrate silicon-based analytical chains such as sampling, gas injection, and mixture separation to enhance specificity, detection, identification, and quantification of compounds.

Energy Dome

Venture Round in 2022
Energy Dome develops a low-cost, efficient system for long-duration electricity storage using liquid CO2. Its focus is on enabling dispatchable renewable energy production to facilitate the decarbonization of the energy industry and promote sustainability.

Fineheart

Grant in 2022
Fineheart is a France-based medical device company specializing in innovative technologies for cardiovascular care. It focuses on the development of implantable cardiac devices aimed at treating cardiovascular diseases. The company's flagship product is a novel, wirelessly powered, fully implantable mechanical circulatory support device. This device is designed to optimize cardiac output while preserving the heart's natural contractility, thereby enabling patients to restore normal cardiac function. Fineheart's technology aims to improve the quality of life for heart failure patients, allowing them to return to normal daily activities.

Fineheart

Series C in 2022
Fineheart is a France-based medical device company specializing in innovative technologies for cardiovascular care. It focuses on the development of implantable cardiac devices aimed at treating cardiovascular diseases. The company's flagship product is a novel, wirelessly powered, fully implantable mechanical circulatory support device. This device is designed to optimize cardiac output while preserving the heart's natural contractility, thereby enabling patients to restore normal cardiac function. Fineheart's technology aims to improve the quality of life for heart failure patients, allowing them to return to normal daily activities.

Tilkal

Venture Round in 2022
Tilkal develops a software infrastructure that organizes traceability across various supply chain stakeholders. Founded in 2017, the company is headquartered in Paris, France.

Tilkal

Grant in 2022
Tilkal develops a software infrastructure that organizes traceability across various supply chain stakeholders. Founded in 2017, the company is headquartered in Paris, France.

Nexdot

Grant in 2022
Nexdot is a company specializing in the development and production of semiconductor nanocrystals known as Quantum Dots, with a particular focus on nanoplatelets—two-dimensional nanosheet Quantum Dots that exhibit enhanced properties. Originating as a spin-off from a renowned academic laboratory in Paris, Nexdot leverages over a decade of expertise in nanomaterial research. The company has invested four years in intensive research and development to establish unique capabilities in the synthesis of colloidal Quantum Dots and Nanoplatelets. Their proprietary materials, characterized by controlled shape and composition, are designed for a variety of applications, including displays, lighting, energy storage, detectors, and bio-imaging. Nexdot combines a team of highly skilled, passionate scientists with seasoned executives who possess a strong background in management and innovation leadership, positioning the company as a leader in the field.

ELEM Biotech

Grant in 2022
ELEM Biotech SL is a biomedical software company based in Barcelona, Spain, that specializes in creating virtual human models through advanced mathematical modeling and cloud computing. Founded in 2018 by researchers from the Barcelona Supercomputing Center, ELEM has developed a suite of simulation tools known as Alya Red. This platform operates on a Software-as-a-Service model and is designed for the medical device and pharmaceutical industries. Alya Red allows for the simulation of cardiovascular and respiratory systems on virtual patients, utilizing high-performance computing, computational biomechanics, and data analysis. These virtual avatars enable biomedical companies and healthcare professionals to enhance diagnostics, plan treatments, optimize drug delivery, and improve medical devices.

Ganymed Robotics

Series B in 2022
Ganymed Robotics is a medical device company that develops robotics technologies for orthopedic surgeons, including a therapeutic device designed to improve precision in knee replacement procedures. Founded in 2018 and based in Paris, the company aims to enhance surgical accuracy, reduce operating times, and improve patient outcomes by integrating robotics into the orthopedic workflow.

Onward

Grant in 2022
Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

C12 Quantum Electronics

Grant in 2022
C12 Quantum Electronics is a company based in Paris, Ile-de-France, France, founded in 2019 by Pierre and Matthieu Desjardins. The company focuses on developing reliable quantum processors utilizing carbon nanotubes, which significantly reduce error rates. This technology positions C12 Quantum Electronics as a strong candidate for noisy intermediate-scale quantum applications. In addition to building quantum computers, the company also engages in developing and accelerating experiments related to information processing systems, allowing industrial clients to leverage intermediate-scale quantum applications for enhanced computing capabilities.

Qarnot

Grant in 2022
Founded in 2010, Qarnot is a French company that designs and develops innovative computing heaters, embedding microprocessors as heat sources connected to the internet. These devices, known as Q.rad, provide economical and ecological cloud HPC solutions, repurposing server heat to warm buildings while offering affordable high-performance computing services.

Antabio

Venture Round in 2022
Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

Quanturi Oy

Venture Round in 2022
Quanturi Oy is a Finnish company founded in 2016, headquartered in Espoo, with additional locations across Europe, including France, Great Britain, the Netherlands, Switzerland, Italy, and Belgium. The company specializes in developing and providing continuous monitoring solutions for fermentable products, focusing on sectors such as agriculture, forestry, and waste management. Its product offerings include wireless monitoring systems for compost temperature, grain management, and hay, as well as temperature monitoring systems applicable to various other industries. Quanturi Oy also engages in online sales of its innovative solutions, emphasizing the analysis of data associated with its connected objects.

Quanturi Oy

Grant in 2022
Quanturi Oy is a Finnish company founded in 2016, headquartered in Espoo, with additional locations across Europe, including France, Great Britain, the Netherlands, Switzerland, Italy, and Belgium. The company specializes in developing and providing continuous monitoring solutions for fermentable products, focusing on sectors such as agriculture, forestry, and waste management. Its product offerings include wireless monitoring systems for compost temperature, grain management, and hay, as well as temperature monitoring systems applicable to various other industries. Quanturi Oy also engages in online sales of its innovative solutions, emphasizing the analysis of data associated with its connected objects.

Abzu

Grant in 2022
Abzu is a company that develops a scientific artificial intelligence platform aimed at accelerating drug discovery and bringing pharmaceuticals to market more efficiently. Founded in January 2018, with offices in Copenhagen, Denmark, and Barcelona, Spain, Abzu challenges traditional, opaque AI methods by utilizing its pioneering technology, the QLattice. This platform provides transparent and explainable models that enable data scientists to approach their work with a scientific mindset. By unlocking new disease mechanisms, discovering novel biomarkers, and designing improved drugs, Abzu empowers pharmaceutical and biotech companies to validate multiple targets simultaneously, thereby enhancing their research capabilities and reducing development costs.

Antabio

Grant in 2022
Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

C2C NewCap

Venture Round in 2022
C2C NewCap, founded in 2014 by Rui Silva and Andre Mao de Ferro, is a Lisbon-based manufacturer specializing in the production of supercapacitors designed for efficient electrical energy storage. The company focuses on developing next-generation devices that utilize proprietary electrodes and an aqueous electrolyte, which contribute to a low environmental impact. C2C NewCap aims to provide clients with energy storage solutions that not only enhance operational efficiency but also reduce overall environmental and operational costs.

SiPearl

Grant in 2022
SiPearl is a French semiconductor company specializing in designing high-performance, low-power microprocessors for exascale supercomputers. Its flagship product, Rhea, based on Arm Neoverse V1 architecture and manufactured using TSMC's N6 or better processes, aims to advance computing infrastructure for critical applications such as HPC, AI, and data centers.

SiPearl

Series A in 2022
SiPearl is a French semiconductor company specializing in designing high-performance, low-power microprocessors for exascale supercomputers. Its flagship product, Rhea, based on Arm Neoverse V1 architecture and manufactured using TSMC's N6 or better processes, aims to advance computing infrastructure for critical applications such as HPC, AI, and data centers.

Qubit Pharmaceuticals

Seed Round in 2022
Qubit Pharmaceuticals is a Paris-based company established in 2020, focusing on innovative technology for pharmaceutical drug discovery. Founded by prominent academic institutions and researchers, including CNAM, CNRS, the University of Texas at Austin, Sorbonne University, and Washington University, the company leverages over 20 years of research and development. Qubit Pharmaceuticals has developed a drug discovery simulation platform that aims to significantly reduce the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, the platform facilitates virtual screening and visualization of potential drug candidates. By integrating principles of quantum physics, Qubit Pharmaceuticals supports biopharmaceutical companies in accelerating their research and development processes, ultimately enhancing the efficiency of drug discovery.

Core Biogenesis

Private Equity Round in 2022
Founded in Paris, France in 2020, Core Biogenesis specializes in developing protein production technologies. The company employs proprietary gene editing and plant biotechnology to significantly lower the cost of producing growth factors, which are crucial molecules in clean meat and cell therapy industries.

Ignion

Venture Round in 2022
Founded in 2015, Ignion specializes in designing and manufacturing antennas tailored for mobile and wireless connectivity. Their off-the-shelf antennas cater to Internet of Things devices, mobile connectivity, and short-range wireless systems, facilitating seamless integration within industrial designs.

Core Biogenesis

Grant in 2022
Founded in Paris, France in 2020, Core Biogenesis specializes in developing protein production technologies. The company employs proprietary gene editing and plant biotechnology to significantly lower the cost of producing growth factors, which are crucial molecules in clean meat and cell therapy industries.

Easyl

Grant in 2022
Easyl is a manufacturer based in Bonneville, France, specializing in the sustainable production of materials for zinc-based batteries. Founded in 2017, the company employs green chemistry to create composites primarily using calcium zincate. This innovative approach allows Easyl to develop advanced electrodes that enhance the performance of batteries by optimizing their electrochemical characteristics. By focusing on environmentally friendly methods, Easyl aims to contribute to the growing demand for sustainable energy solutions in the battery manufacturing industry.

Scipio Bioscience

Venture Round in 2022
Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

Ignion

Grant in 2022
Founded in 2015, Ignion specializes in designing and manufacturing antennas tailored for mobile and wireless connectivity. Their off-the-shelf antennas cater to Internet of Things devices, mobile connectivity, and short-range wireless systems, facilitating seamless integration within industrial designs.

Scipio Bioscience

Grant in 2022
Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

Dracula Technologies

Grant in 2022
Founded in 2011 and headquartered in Valence, France, Dracula Technologies designs and manufactures organic photovoltaic cells. These cells convert ambient light into electricity, enabling small devices like phones and sensors to recharge themselves. The company's flagship product, Light As Your Energetic Response (LAYER), is used indoors and outdoors.

Cailabs

Grant in 2022
CAILabs SAS is a French deep tech company headquartered in Rennes, specializing in the design, development, and production of photonic solutions aimed at optimizing light utilization in various applications. Established in 2013, CAILabs focuses on innovative optical components, particularly through its patented Multi-Plane Light Conversion (MPLC) technology. The company provides a range of products, including mode multiplexers, light converters, and laser beam shaping solutions tailored for the telecommunications and industrial laser sectors. Its offerings are designed to enhance the performance of fiber optic networks and laser material processing, addressing critical challenges such as atmospheric turbulence and the need for efficient signal multiplexing. CAILabs aims to leverage its expertise and technological innovations to create reliable and cost-effective solutions for clients in the photonics industry.

PeekMed

Grant in 2022
Founded in 2015 by Jaime Campos, Sara Silva, and João Pedro Ribeiro, PeekMed specializes in developing a 3D pre-operative planning system for orthopedic surgery. Its software enables surgeons to plan various procedures, such as total joint replacements and fracture reductions, aiming to improve patient outcomes while reducing costs.

SAALG Geomechanics

Venture Round in 2022
Founded in 2016, SAALG Geomechanics specializes in real-time ground analysis software for civil works and building projects. It offers machine learning-driven solutions to anticipate ground movement issues, along with numerical models calibrations, soil parameter characterization, and geotechnical consulting services.

Core Biogenesis

Venture Round in 2022
Founded in Paris, France in 2020, Core Biogenesis specializes in developing protein production technologies. The company employs proprietary gene editing and plant biotechnology to significantly lower the cost of producing growth factors, which are crucial molecules in clean meat and cell therapy industries.

SAALG Geomechanics

Grant in 2022
Founded in 2016, SAALG Geomechanics specializes in real-time ground analysis software for civil works and building projects. It offers machine learning-driven solutions to anticipate ground movement issues, along with numerical models calibrations, soil parameter characterization, and geotechnical consulting services.

Multiverse Computing

Grant in 2021
Multiverse Computing SL is a software development company based in San Sebastian, Spain, with an additional office in Toronto, Canada. Established in 2019, the company specializes in creating quantum computing software that leverages probabilistic and nondeterministic technologies to address complex challenges in various sectors, particularly finance. Multiverse Computing's software solutions are designed for portfolio optimization, risk analysis, and market simulation, enabling clients in industries such as banking, energy, manufacturing, and logistics to harness the power of quantum computing. By focusing on these tailored applications, the company aims to facilitate advancements in solving financial and macro-economic problems, positioning itself as a key player in the emerging quantum technology landscape.

Multiverse Computing

Venture Round in 2021
Multiverse Computing SL is a software development company based in San Sebastian, Spain, with an additional office in Toronto, Canada. Established in 2019, the company specializes in creating quantum computing software that leverages probabilistic and nondeterministic technologies to address complex challenges in various sectors, particularly finance. Multiverse Computing's software solutions are designed for portfolio optimization, risk analysis, and market simulation, enabling clients in industries such as banking, energy, manufacturing, and logistics to harness the power of quantum computing. By focusing on these tailored applications, the company aims to facilitate advancements in solving financial and macro-economic problems, positioning itself as a key player in the emerging quantum technology landscape.

Aortyx

Grant in 2021
Aortyx is a pioneering company founded by researchers from IQS School of Engineering and Hospital Clínic de Barcelona. It specializes in developing endovascular devices designed to treat aortic diseases, focusing on tissue regeneration through mimicking the aorta's biomechanical environment.

CARTO

Series C in 2021
Carto is a location intelligence platform that turns spatial data into actionable insights for logistics, marketing, and site optimization. The cloud-based mapping, analysis, and visualization engine enables data scientists, developers, and analysts to treat location as an active analytical dimension, solving spatial problems, optimizing business processes, and predicting outcomes. Founded in 2012 and headquartered in New York City, Carto operates with offices in Madrid, Seville, and Washington, DC, and serves thousands of customers worldwide, including Mastercard, Vodafone, Bain & Company, and Coca-Cola, with hundreds of thousands of users. The company is backed by leading venture investors Accel Partners, Salesforce Ventures, Earlybird Ventures, and Kibo Ventures, underscoring its position in location intelligence.

Daze

Seed Round in 2021
Daze is an engineering startup focused on creating innovative solutions for electric vehicle charging. Its flagship product, DazePlug, is an automatic charging device that utilizes smart charging ecosystems and energy management systems. This technology enables automatic inductive charging, significantly reducing the time required to charge electric vehicles while eliminating the need for manual handling of cables. DazePlug features a retrofit design that is both waterproof and dustproof, ensuring durability and ease of use. By simplifying the charging process, Daze aims to enhance user experience and convenience for electric vehicle owners.

Criam

Grant in 2021
Criam is a Portuguese biotechnology company based in Braga that develops portable diagnostic technology for blood typing and infectious disease detection. Its stand-alone platform does not require electricity or laboratory infrastructure, enabling rapid testing at the point of care. A single reader can perform multiple tests using cartridges and computer vision algorithms to detect a broad range of diseases, including HIV, with real-time data to support clinical decisions. The system leverages lab-on-a-chip concepts and biomarker detection algorithms to deliver fast, user-friendly, and cost-effective diagnostics in diverse settings, including remote environments and emergency care.

EVerZom

Grant in 2021
Founded in 2019, EVerZom is a Paris-based biotech company specializing in nanomedicine. It develops and manufactures extracellular vesicles (exosomes, microvesicles, apoptotic bodies) at commercial scale under Good Manufacturing Practice (GMP) standards for pharmaceutical applications in regenerative medicine and drug delivery.

Voiseed

Grant in 2021
Voiseed is an Italian startup focused on artificial intelligence in synthetic speech technology. The company has developed a fast and scalable AI Dubbing Platform specifically for the video game industry, enabling the creation of virtual human voices that mimic human emotions and prosody. This cloud-based software leverages advanced generative AI technologies to produce highly expressive virtual voices, allowing creators to customize vocal expressions and achieve multilingual voice conversion for various projects. By streamlining the dubbing process, Voiseed aims to reduce costs, time, and complexity, while continuously expanding its features to cater to additional sectors beyond gaming.

Ganymed Robotics

Grant in 2021
Ganymed Robotics is a medical device company that develops robotics technologies for orthopedic surgeons, including a therapeutic device designed to improve precision in knee replacement procedures. Founded in 2018 and based in Paris, the company aims to enhance surgical accuracy, reduce operating times, and improve patient outcomes by integrating robotics into the orthopedic workflow.

ENERSENS

Venture Round in 2021
Enersens is a firm that produces silica aerogel products. The company was founded in 2010 and is based in Les Auvergnes, France.

NETRIS Pharma

Grant in 2021
NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.

Wooptix

Venture Round in 2021
Wooptix S.L., founded in 2014 and headquartered in Madrid, Spain, specializes in developing advanced imaging technologies. The company focuses on light field and wavefront phase imaging software that captures comprehensive information about light, utilizing the full resolution of sensors. Wooptix's platform enables the three-dimensional modulation of images, allowing for higher data points at elevated frame rates in volumetric images and videos. This technology facilitates enhanced image quality and advanced post-processing capabilities, providing users with innovative ways to interact with and visualize their environments. Wooptix aims to improve human experiences through its cutting-edge imaging solutions.

NETRIS Pharma

Venture Round in 2021
NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.

MYSPHERA

Venture Round in 2021
MYSPHERA SL is a company based in Paterna, Spain, that specializes in developing location and process visibility solutions for the healthcare sector using Internet of Things (IoT) technology and real-time location systems (RTLS). Established in 2012, MYSPHERA offers a range of IoT devices and applications designed to enhance patient care and operational efficiency in acute care hospitals, senior living facilities, and patient homes. Its solutions include tracking systems for residents and nursing services, as well as alerts for patients. The company also provides various web applications, such as MYHOSPITAL, MYNURSING, and MYLOCS, which assist healthcare professionals and administrators in managing services effectively. By delivering actionable insights through smart sensors, MYSPHERA aims to improve patient outcomes and optimize resource management across healthcare organizations in Europe, the Middle East, and Latin America.

SiPearl

Venture Round in 2021
SiPearl is a French semiconductor company specializing in designing high-performance, low-power microprocessors for exascale supercomputers. Its flagship product, Rhea, based on Arm Neoverse V1 architecture and manufactured using TSMC's N6 or better processes, aims to advance computing infrastructure for critical applications such as HPC, AI, and data centers.

MYSPHERA

Grant in 2021
MYSPHERA SL is a company based in Paterna, Spain, that specializes in developing location and process visibility solutions for the healthcare sector using Internet of Things (IoT) technology and real-time location systems (RTLS). Established in 2012, MYSPHERA offers a range of IoT devices and applications designed to enhance patient care and operational efficiency in acute care hospitals, senior living facilities, and patient homes. Its solutions include tracking systems for residents and nursing services, as well as alerts for patients. The company also provides various web applications, such as MYHOSPITAL, MYNURSING, and MYLOCS, which assist healthcare professionals and administrators in managing services effectively. By delivering actionable insights through smart sensors, MYSPHERA aims to improve patient outcomes and optimize resource management across healthcare organizations in Europe, the Middle East, and Latin America.

APIX Analytics

Grant in 2021
Founded in 2014, APIX Analytics specializes in developing miniaturized multigas analyzers systems. These systems integrate silicon-based analytical chains such as sampling, gas injection, and mixture separation to enhance specificity, detection, identification, and quantification of compounds.

Spika Tech

Venture Round in 2021
Spika Tech is a technology-focused company based in Madrid, Spain, founded in 2015. It specializes in research and development, providing comprehensive support for projects in various technological sectors. The company offers a wide range of services, including virtual and augmented reality, the development of complex software applications, and artificial intelligence solutions. Additionally, Spika Tech assists clients with branding and design needs, such as creating logos, corporate identities, presentations, websites, applications, and online stores. By leveraging the latest techniques in design and programming, Spika Tech aims to enhance the quality and effectiveness of its clients' development processes.

Wooptix

Grant in 2021
Wooptix S.L., founded in 2014 and headquartered in Madrid, Spain, specializes in developing advanced imaging technologies. The company focuses on light field and wavefront phase imaging software that captures comprehensive information about light, utilizing the full resolution of sensors. Wooptix's platform enables the three-dimensional modulation of images, allowing for higher data points at elevated frame rates in volumetric images and videos. This technology facilitates enhanced image quality and advanced post-processing capabilities, providing users with innovative ways to interact with and visualize their environments. Wooptix aims to improve human experiences through its cutting-edge imaging solutions.

Spika Tech

Grant in 2021
Spika Tech is a technology-focused company based in Madrid, Spain, founded in 2015. It specializes in research and development, providing comprehensive support for projects in various technological sectors. The company offers a wide range of services, including virtual and augmented reality, the development of complex software applications, and artificial intelligence solutions. Additionally, Spika Tech assists clients with branding and design needs, such as creating logos, corporate identities, presentations, websites, applications, and online stores. By leveraging the latest techniques in design and programming, Spika Tech aims to enhance the quality and effectiveness of its clients' development processes.

SiPearl

Grant in 2021
SiPearl is a French semiconductor company specializing in designing high-performance, low-power microprocessors for exascale supercomputers. Its flagship product, Rhea, based on Arm Neoverse V1 architecture and manufactured using TSMC's N6 or better processes, aims to advance computing infrastructure for critical applications such as HPC, AI, and data centers.

Palobiofarma

Venture Round in 2021
Palobiofarma is a Spanish biotechnology company based in Barcelona’s Science Park, dedicated to discovering and developing innovative drugs that target adenosine receptors. The company aims to be the first European entity to bring an adenosine modulator to market, focusing on the treatment of diseases such as advanced prostate cancer. Through its expertise in medicinal chemistry and in vitro pharmacology, Palobiofarma is committed to advancing the understanding of adenosine's role in disease and enabling healthcare professionals to improve patient outcomes through novel therapeutic options.

Epigene Labs

Grant in 2021
Epigene Labs SAS is a biotechnology firm focused on enhancing precision oncology through its advanced technology platform that utilizes artificial intelligence. Founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, the company addresses the significant challenges of aggregating, analyzing, and visualizing extensive genomic data in cancer research. By integrating proprietary data from partners with publicly available datasets, Epigene Labs provides medical researchers with actionable insights and user-friendly analytics. The company collaborates with leading cancer centers and prominent biotech firms to develop intelligence-augmenting services that support drug discovery and research in precision oncology. Its innovative approach aims to transform genomic data into effective strategies for targeted cancer therapies.

ENERSENS

Grant in 2021
Enersens is a firm that produces silica aerogel products. The company was founded in 2010 and is based in Les Auvergnes, France.

Palobiofarma

Grant in 2021
Palobiofarma is a Spanish biotechnology company based in Barcelona’s Science Park, dedicated to discovering and developing innovative drugs that target adenosine receptors. The company aims to be the first European entity to bring an adenosine modulator to market, focusing on the treatment of diseases such as advanced prostate cancer. Through its expertise in medicinal chemistry and in vitro pharmacology, Palobiofarma is committed to advancing the understanding of adenosine's role in disease and enabling healthcare professionals to improve patient outcomes through novel therapeutic options.

PKvitality

Series A in 2021
PKvitality is a French bio-wearable company founded in 2017. It specializes in developing non-invasive health monitoring devices, notably the K’Watch Glucose, a smartwatch that enables diabetic patients to monitor their glucose levels painlessly and discreetly.

Aenitis Technologies

Grant in 2021
A French startup created by CNRS researchers at the Physics and Mechanics of Heterogeneous Media (PMMH) Laboratory in Paris, Aenitis Technologies develops bioprocessing medical devices that use acoustophoresis to separate, manipulate and filter biological elements, with a focus on cell therapy manufacturing such as cell sorting, washing and isolation for cell therapy units and blood banks. The company aims to provide acoustic preparation solutions to streamline cell therapies and advance public health, pursuing leadership in acoustophoresis-based separation.

Oledcomm

Grant in 2021
Oledcomm designs and develops LiFi solutions that enable high-speed optical wireless data communication for aerospace and industrial markets. Its product portfolio includes LiFi transceivers, software, and LiFi network interface devices that convert information into binary data for fast, secure wireless transmission in telecom, datacom, consumer electronics, and industrial applications, especially where radio waves are undesirable. Founded in 2012 and based in Paris, France, the company was re-founded in 2020 by Benjamin Azoulay.

Oledcomm

Venture Round in 2021
Oledcomm designs and develops LiFi solutions that enable high-speed optical wireless data communication for aerospace and industrial markets. Its product portfolio includes LiFi transceivers, software, and LiFi network interface devices that convert information into binary data for fast, secure wireless transmission in telecom, datacom, consumer electronics, and industrial applications, especially where radio waves are undesirable. Founded in 2012 and based in Paris, France, the company was re-founded in 2020 by Benjamin Azoulay.

SAS SABI AGRI

Grant in 2021
Founded in 2017, SAS SABI AGRI specializes in designing and manufacturing electric tractors for diverse agricultural projects such as market gardening, livestock farming, field crops, vine-growing, and arboriculture.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.